130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor. (December 2022) - Sullivan, R.J.; Sharma, M.R.; Vaena, D.; Hamilton, E.; Izar, B.; Rasco, D.; Gainor, J.; D. Shepard,; Papadopoulos, K.; Dumbrava, E.E.; Adewoye, H.H.; Ferre, P.J.; et al.